|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
CN1960728A
(zh)
*
|
2004-01-16 |
2007-05-09 |
密歇根大学董事会 |
构象受限的smac模拟物及其应用
|
|
EP1715882A4
(en)
*
|
2004-01-16 |
2009-04-08 |
Univ Michigan |
SMAC-PEPTIDOMIMETIKA AND ITS USES
|
|
SG152225A1
(en)
|
2004-04-07 |
2009-05-29 |
Novartis Ag |
Inhibitors of iap
|
|
RS53734B1
(sr)
*
|
2004-07-02 |
2015-06-30 |
Genentech Inc. |
Inhibitori iap
|
|
US7674787B2
(en)
*
|
2004-07-09 |
2010-03-09 |
The Regents Of The University Of Michigan |
Conformationally constrained Smac mimetics and the uses thereof
|
|
US20100190688A1
(en)
*
|
2004-07-12 |
2010-07-29 |
Bin Chao |
Tetrapeptide analogs
|
|
WO2006020060A2
(en)
|
2004-07-15 |
2006-02-23 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
|
CN101146803A
(zh)
|
2004-12-20 |
2008-03-19 |
健泰科生物技术公司 |
Iap的吡咯烷抑制剂
|
|
PL1851200T3
(pl)
*
|
2005-02-25 |
2014-06-30 |
Tetralogic Pharm Corp |
Dimeryczne inhibitory IAP
|
|
JP4954983B2
(ja)
|
2005-05-18 |
2012-06-20 |
ファーマサイエンス・インコーポレイテッド |
Ｂｉｒドメイン結合化合物
|
|
CA2617642A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US7589118B2
(en)
*
|
2005-10-25 |
2009-09-15 |
Aegera Therapeutics, Inc. |
IAP BIR domain binding compounds
|
|
NZ594746A
(en)
*
|
2005-12-19 |
2013-03-28 |
Genentech Inc |
Inhibitors of iap
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
AU2007250443B2
(en)
*
|
2006-05-16 |
2013-06-13 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
JP5452223B2
(ja)
*
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Ｉａｐ阻害剤
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014236A1
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014238A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
CN101516904A
(zh)
|
2006-07-24 |
2009-08-26 |
泰特拉洛吉克药业公司 |
二聚的iap拮抗剂
|
|
US20100144650A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20080951A1
(es)
|
2006-08-02 |
2008-09-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
WO2008024390A2
(en)
*
|
2006-08-24 |
2008-02-28 |
Novartis Ag |
2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
|
|
AU2007299870A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Novartis Ag |
Heterocyclic organic compounds
|
|
CA2666112A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as iap inhibitors
|
|
WO2008079735A1
(en)
*
|
2006-12-19 |
2008-07-03 |
Genentech, Inc. |
Imidazopyridine inhibitors of iap
|
|
EA200900820A1
(ru)
*
|
2006-12-20 |
2010-02-26 |
Новартис Аг |
2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд)
|
|
NZ580313A
(en)
*
|
2007-04-12 |
2011-11-25 |
Joyant Pharmaceuticals Inc |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
|
PE20130150A1
(es)
*
|
2007-04-30 |
2013-02-27 |
Genentech Inc |
Inhibidores de las iap
|
|
EP2156189A1
(en)
*
|
2007-05-07 |
2010-02-24 |
Tetralogic Pharmaceuticals Corp. |
Tnf gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
SI2240506T1
(sl)
*
|
2008-01-11 |
2013-04-30 |
Genentech, Inc. |
Inhibitorji IAP
|
|
US20110117081A1
(en)
*
|
2008-05-05 |
2011-05-19 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
AU2009261919A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Pharmascience Inc. |
Bridged secondary amines and use thereof as IAP BIR domain binding compounds
|
|
NZ590550A
(en)
|
2008-08-02 |
2013-05-31 |
Genentech Inc |
Inhibitors of Apoptosis (IAP) for treating cancer
|
|
CA2730357A1
(en)
*
|
2008-08-16 |
2010-02-25 |
Genetech, Inc. |
Azaindole inhibitors of iap
|
|
CA2736505A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
Iap inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
US20120196793A1
(en)
|
2009-09-18 |
2012-08-02 |
Firestone Brant G |
Biomarkers for iap inhibitor compounds
|
|
EP2493879B1
(en)
|
2009-10-28 |
2014-05-14 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
CN102985439B9
(zh)
|
2010-02-12 |
2016-08-03 |
制药科学股份有限公司 |
Iap bir结构域结合化合物
|
|
AU2011240070A1
(en)
|
2010-04-16 |
2012-11-08 |
Bayer Intellectual Property Gmbh |
Heterocyclic compounds as pest control agents
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
WO2013049350A1
(en)
|
2011-09-30 |
2013-04-04 |
Tetralogic Pharmaceuticals Corporation |
Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
MX2014013429A
(es)
|
2012-05-04 |
2014-12-08 |
Novartis Ag |
Biomarcadores para la terapia inhibidora de iap.
|
|
WO2014085489A1
(en)
|
2012-11-30 |
2014-06-05 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
KR20150131173A
(ko)
|
2013-03-15 |
2015-11-24 |
노파르티스 아게 |
항체 약물 접합체
|
|
KR20200108903A
(ko)
|
2013-06-25 |
2020-09-21 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN109336883B
(zh)
|
2013-12-20 |
2022-06-14 |
阿斯特克斯治疗有限公司 |
双环杂环化合物及其治疗用途
|
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9811383B2
(en)
*
|
2014-05-05 |
2017-11-07 |
Empire Technology Development Llc |
Processing a composite task based on a semantic relation graph
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
SG11201700254QA
(en)
|
2014-08-12 |
2017-02-27 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates
|
|
GB201414730D0
(en)
*
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
HK1245791A1
(zh)
|
2015-01-20 |
2018-08-31 |
阿尔维纳斯运营股份有限公司 |
用於雄激素受体的靶向降解的化合物和方法
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
|
AU2017282651B2
(en)
|
2016-06-21 |
2021-08-12 |
Orion Ophthalmology LLC |
Heterocyclic prolinamide derivatives
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
WO2018102725A1
(en)
|
2016-12-01 |
2018-06-07 |
Arvinas, Inc. |
Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
|
|
EP3558994A4
(en)
|
2016-12-23 |
2021-05-12 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES
|
|
BR112019012682A2
(pt)
|
2016-12-23 |
2019-12-17 |
Arvinas Operations Inc |
moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
BR112019015312A2
(pt)
|
2017-01-26 |
2020-03-10 |
Arvinas Operations, Inc. |
Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
US11179413B2
(en)
|
2017-03-06 |
2021-11-23 |
Novartis Ag |
Methods of treatment of cancer with reduced UBB expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018215936A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
JP7257397B2
(ja)
*
|
2017-11-13 |
2023-04-13 |
チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド |
Ｉａｐ阻害剤として有用なｓｍａｃ模倣物及びその用途
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
WO2019154053A1
(zh)
*
|
2018-02-09 |
2019-08-15 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
CA3103385A1
(en)
|
2018-07-10 |
2020-01-16 |
Novartis Ag |
3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
IL281188B2
(en)
|
2018-09-07 |
2025-08-01 |
Arvinas Operations Inc |
Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
JP2022514315A
(ja)
|
2018-12-20 |
2022-02-10 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
|
|
AU2019409132A1
(en)
|
2018-12-21 |
2021-07-15 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020222346B2
(en)
|
2019-02-15 |
2021-12-09 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3132740A1
(en)
*
|
2019-03-07 |
2020-09-10 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Combination of iap inhibitor and immune checkpoint inhibitor
|
|
AU2020274768B2
(en)
*
|
2019-05-10 |
2025-06-26 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystalline form of smac mimic used as iap inhibitor and preparation method thereof
|
|
CN114867727B
(zh)
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
US20220257698A1
(en)
|
2019-08-02 |
2022-08-18 |
Lanthiopep B.V. |
Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
|
|
CN118986983A
(zh)
|
2019-08-26 |
2024-11-22 |
阿尔维纳斯运营股份有限公司 |
用四氢萘衍生物作为雌激素受体降解剂的治疗乳腺癌的方法
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
JP2023510426A
(ja)
|
2020-01-20 |
2023-03-13 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
|
|
CN116134027B
(zh)
|
2020-08-03 |
2025-01-24 |
诺华股份有限公司 |
杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
WO2022056368A1
(en)
|
2020-09-14 |
2022-03-17 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
JP2024517409A
(ja)
|
2021-04-16 |
2024-04-22 |
ノバルティス アーゲー |
抗体薬物結合体及びその作成方法
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
AU2023314354A1
(en)
|
2022-07-26 |
2024-11-21 |
Novartis Ag |
Crystalline forms of an akr1c3 dependent kars inhibitor
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
KR20250151412A
(ko)
|
2023-01-26 |
2025-10-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
세레블론계 kras 분해 단백질 및 이와 관련된 용도
|